Compare Amgen, Inc. (AMGN) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Yum China Holdings Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Yum China Holdings Inc trades at $43.99 (market cap $14.80B). The key difference: Amgen, Inc. is far larger — about 13.3× Yum China Holdings Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | YUMC | |
|---|---|---|
Market Cap | $196.12B | $14.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $57.95 |
52-Week Low | $271.18 | $40.18 |
Enterprise Value | $241.41B | $15.69B |
Dividend Yield | 2.77% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
YUMC trades at $43.02, up 1.68% today, with a neutral technical signal and strong fundamentals including consistent earnings beats. Revenue grew to $11.80B in 2025, with a net margin of 7.83%. The company recently announced a $0.29 dividend and a $512M share repurchase, while acquiring full ownership of Pizza Hut in mainland China, signaling strategic expansion.
Outlook remains positive with analyst consensus at 74% buy ratings, though risks include China's competitive dining market and currency volatility. The stock's P/E of 16.48 and ROE of 16.87% support value, but investors should monitor Q2 2026 earnings due July 30, 2026, for growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
